Clinical Trial Update: AZD9291 US Expanded Access Program

View source ↗

Summary

A US expanded access program for AZD9291 (osimertinib) in EGFR T790M mutation-positive non-small cell lung cancer is no longer available.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• AZD9291 (osimertinib) (osimertinib)

Snippet

Sponsor: AstraZeneca | Conditions: EGFR T790M Mutation Positive NSCLC | Status: NO_LONGER_AVAILABLE